Under a tenth of individuals who could benefit from weight-loss injections such as Wegovy are able to get them, caution the WHO as it releases its first recommendations on the medications.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for increased and just access to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our latest guidelines recognises that obesity is a long-term condition that can be treated with comprehensive and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are major hurdles to widespread access to the treatments that can assist patients in reducing significant body mass, explains the organization.
GLP-1 Therapy Scarcity
Even in the present best projected outlook, the production of these medications would only suffice for about 100 million people – less than 10% of the global need, per the WHO.
The advice calls on countries and companies to widen availability, via strategies like patent sharing.
A patent on semaglutide – the primary component of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Weight-Loss Drugs Function
The injections imitate a biological compound to slow digestion, suppress the appetite and increase feelings of fullness so people consume fewer calories.
Individuals typically start to lose weight in the initial weeks of starting on the once-weekly jabs.
Evidence points to users may put most of the weight back on within a year of halting the medication, as their typical appetite return.
To be above a healthy weight increases your likelihood for experiencing medical conditions, including type 2 diabetes, heart disease, brain attack, and some cancers.
Obesity concerns people in countries worldwide and was associated with millions of deaths worldwide in 2024, per the health agency.
